Research Analysts Set Expectations for BCRX Q4 Earnings

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) – Analysts at HC Wainwright reduced their Q4 2025 earnings per share estimates for BioCryst Pharmaceuticals in a report released on Tuesday, November 4th. HC Wainwright analyst A. Fein now expects that the biotechnology company will earn $0.00 per share for the quarter, down from their prior forecast of $0.02. The consensus estimate for BioCryst Pharmaceuticals’ current full-year earnings is ($0.36) per share. HC Wainwright also issued estimates for BioCryst Pharmaceuticals’ FY2026 earnings at $0.01 EPS, FY2027 earnings at $0.33 EPS and FY2028 earnings at $0.84 EPS.

A number of other analysts also recently weighed in on BCRX. Evercore ISI reissued an “in-line” rating and set a $8.00 target price on shares of BioCryst Pharmaceuticals in a research report on Wednesday, October 1st. Weiss Ratings reiterated a “sell (d-)” rating on shares of BioCryst Pharmaceuticals in a research report on Wednesday, October 8th. Wall Street Zen raised shares of BioCryst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, July 26th. TD Cowen assumed coverage on shares of BioCryst Pharmaceuticals in a research report on Wednesday, October 15th. They set a “buy” rating and a $30.00 price target on the stock. Finally, Cantor Fitzgerald increased their price target on BioCryst Pharmaceuticals from $24.00 to $26.00 and gave the stock an “overweight” rating in a report on Wednesday, October 15th. Ten investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $19.33.

BioCryst Pharmaceuticals Price Performance

Shares of BCRX opened at $7.09 on Thursday. BioCryst Pharmaceuticals has a 1 year low of $6.00 and a 1 year high of $11.31. The company has a market capitalization of $1.49 billion, a price-to-earnings ratio of -39.39 and a beta of 1.09. The business has a 50-day moving average of $7.45 and a 200-day moving average of $8.66.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its earnings results on Monday, November 3rd. The biotechnology company reported $0.06 EPS for the quarter, missing the consensus estimate of $0.07 by ($0.01). The business had revenue of $159.40 million during the quarter, compared to analysts’ expectations of $162.91 million. During the same quarter in the previous year, the firm earned ($0.07) earnings per share. The company’s revenue for the quarter was up 36.1% on a year-over-year basis. BioCryst Pharmaceuticals has set its FY 2025 guidance at EPS.

Insiders Place Their Bets

In related news, Director Theresa Heggie sold 70,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 13th. The stock was sold at an average price of $8.51, for a total transaction of $595,700.00. Following the transaction, the director directly owned 65,352 shares of the company’s stock, valued at approximately $556,145.52. This represents a 51.72% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 5.10% of the company’s stock.

Institutional Investors Weigh In On BioCryst Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of BCRX. Headlands Technologies LLC acquired a new position in shares of BioCryst Pharmaceuticals during the first quarter worth approximately $32,000. New Age Alpha Advisors LLC bought a new stake in BioCryst Pharmaceuticals during the 1st quarter valued at $62,000. Family Legacy Financial Solutions LLC acquired a new position in BioCryst Pharmaceuticals during the second quarter worth $72,000. Allspring Global Investments Holdings LLC bought a new position in shares of BioCryst Pharmaceuticals in the first quarter valued at $79,000. Finally, Farther Finance Advisors LLC lifted its stake in shares of BioCryst Pharmaceuticals by 326.8% in the third quarter. Farther Finance Advisors LLC now owns 10,590 shares of the biotechnology company’s stock valued at $80,000 after buying an additional 8,109 shares in the last quarter. Institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.